Bro just show us

@YourGrails yourgrails.vercel.app/ I'll knock out some user specific metrics next week. nice job @LHBCrypto gg

Team1 USA Builder Spotlight @CandiJarrett is the co-founder of @XKOVAPAY, building the authentication and payment rails for AI agents on Avalanche. An award-winning novelist who took a seat at the SEC's Crypto Roundtable last fall, Candice brings a rare combination of creative and technical range to everything she builds. What Is XKOVA? XKOVA's easily installable SDK helps agents and humans with wallet management, authentication, and scoped permissions. The SDK supports x402, ACP, and EIP-8004, so AI agents can pay for APIs, complete purchases, and manage subscriptions on behalf of users. x402 handles HTTP-native payments, ACP enables agent-to-merchant transactions, and EIP-8004 is an emerging EVM standard for interoperable agentic payments. In October 2025, @atxwiw3 invited Candice to instruct their web3 founder cohort, backed by @AvaxTeam1, where she shared what years of building blockchain infrastructure look like in practice. Her debut novel, ‘MORTAL TETHER,’ won Top Pick 2024 from the Reader Ready Awards. Her new children's book, ‘No Pea in the Pool,’ drops July 1 and is available for pre-order. Not many builders move between AI agent payments, SEC regulators, and picture books about peas. Candice does, making Avalanche and Team1 better in the process.

I will be participating in the hot emin trials, and the hot emin launch. as part of the hot community.. just wanted to let yall know

Bro just show us

Today, @lifebiosciences confirmed the first patient has been dosed with an epigenetic restoration drug candidate. An exciting milestone 🚀 Life Biosciences is the OG cellular rejuvenation using epigenetic restoration to reverse diseases of aging. It was cofounded by @davidasinclair, who serves as Chairman The company’s proprietary Epigenetic Restoration platform utilizes three transcription factors, OCT4, SOX2, and KLF4 (OSK), to restore older and damaged cells to a younger and healthier state. This innovative approach targets a root cause of aging at the epigenetic level, and has the potential to address a wide range of serious age-related diseases The Phase 1 trial will evaluate the safety and tolerability of ER-100, with additional endpoints assessing visual function. ER‑100 is the first clinical candidate from Life Bio’s Epigenetic Restoration platform, which uses controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK) to restore cellular function by resetting the epigenetic code to more youthful patterns of gene expression “This is an important moment for Life Bio and for the field of aging biology,” said David Sinclair, Ph.D., Co‑founder of Life Biosciences and Professor of Genetics at Harvard Medical School. “Our research has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage. This clinical study represents the first opportunity to test whether restoring that information can ameliorate human disease.” Beyond ER-100, the company is strategically broadening its therapeutic pipeline to address additional age-related diseases, underscoring the platform’s versatility and transformative potential. “This milestone reflects years of rigorous scientific development and translational research,” said Sharon Rosenzweig‑Lipson, Ph.D., Chief Scientific Officer of Life Biosciences. “Our preclinical studies have demonstrated that controlled OSK expression can reset epigenetic patterns associated with healthy cellular function, improve tissue performance, and restore visual function in animal models. Advancing ER‑100 into the clinic is an important step toward translating epigenetic restoration into a new class of medicines for age-related diseases.” Optic neuropathies represent a large unmet medical need. Current treatments primarily address risk factors, such as intraocular pressure in glaucoma, but do not directly target the damage to retinal ganglion cells. As a consequence, the disease often leads to irreversible vision loss despite treatment Vision loss not only directly impacts patients’ lives, but also increases the risk of loss of independence, damaging falls, and depression and dementia due to social isolation, underscoring the need for disease-modifying therapies. Beyond ER‑100, Life Bio is developing applications of its proprietary Epigenetic Restoration platform for multiple indications in a variety of organs, reflecting the broad therapeutic potential of this platform. About Optic Neuropathies Optic neuropathies are a group of disorders characterized by damage to retinal ganglion cells (RGCs), the primary neurons connecting the eye to the brain. Because RGCs do not naturally regenerate, damage results in permanent vision impairment. One such optic neuropathy, open-angle glaucoma (OAG) is a chronic neurodegenerative disease and a leading cause of blindness in older adults While often associated with elevated intraocular pressure, disease progression frequently continues despite treatment, and some patients suffer from OAG despite normal intraocular pressure. Non-arteritic anterior ischemic optic neuropathy (NAION) is the most common acute optic neuropathy in adults over fifty. It involves sudden, painless vision loss due to insufficient blood flow, for which there are currently no approved treatments About ER-100 ER‑100 is an investigational therapy in clinical development for the treatment of optic neuropathies including OAG and NAION. ER‑100 is designed to restore function in retinal ganglion cells using Life Biosciences’ Epigenetic Restoration platform, which utilizes controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK), to reset cellular gene expression patterns and restore cells to a more youthful and functional state. ER‑100 is currently being evaluated in a Phase 1 clinical trial. More information can be found at clinicaltrials.gov (NCT07290244): clinicaltrials.gov/study/NCT… For more information, visit lifebiosciences.com or follow on social media lifebiosciences.com/life-bio…

Bro just show us

I'm just warning you, $PHAR is a train and it will not stop.

DLMM pools are arriving on Pharaoh! Pharaoh has now evolved into the most complete liquidity layer on Avalanche.🔺 With concentrated liquidity, DLMM, and legacy pools all in one place, Pharaoh is now the ONLY DEX IN DeFi built to support all 3 liquidity types. Let’s talk about what makes this so monumental for Pharaoh and @Avax.👇🧵